With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...
Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...
Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...
Nemvaleukin alfa is an investigational engineered fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.
Evaluation of nemvaleukin for platinum-resistant ovarian cancer will be terminated based on OS data from an interim analysis ...
A Waltham company pulled the plug on a Phase 3 cancer trial, while a different Waltham company continued its leadership ...
H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Mural Oncology (MURA) to $6 from $18 and keeps a Buy rating on the ...
Investor's Business Daily on MSN8d
Stock Market Today: Indexes Tick Higher As Apple Helps To Lift Dow; Boeing Flies Higher (Live Coverage)The major indexes show weakened in afternoon action with the Dow Jones struggling for a gain. Apple stock was the biggest ...
Mural Oncology (MURA) announced that the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck’s (MRK) anti-PD-1 therapy, ...
Nemvaleukin alfa with pembrolizumab missed the overall survival primary end point in ARTISTRY-7 for platinum-resistant ...
The company’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback